Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41575-025-01096-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lessons from incretin-based therapy in MASH and obesity.
Nat Rev Gastroenterol Hepatol
August 2025
Department of Medicine, University of Verona, Verona, Italy.
Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.
Endocrine
August 2016
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Viale Europa, 88100, Catanzaro, Italy.
Previous trials of glucose-lowering strategies in subjects with type 2 diabetes have demonstrated a beneficial effect of intensive glycemic control on microvascular complications but failed to show a clear benefit on cardiovascular complications. The findings of meta-analyses of rosiglitazone trials suggesting that rosiglitazone might increase the risk of myocardial infarction have cast doubt on the cardiovascular safety of glucose-lowering drugs. In 2008, the US Food and Drug Administration has implemented rigorous criteria to approve new glucose-lowering drugs, requiring proof of cardiovascular safety.
View Article and Find Full Text PDFIncretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
J Pathol
January 2016
Gene Centre, Centre for Innovative Medical Models (CiMM) and German Centre for Diabetes Research (DZD), Ludwig-Maximilians-Universität München, Germany.
The two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP1), were discovered 45 and 30 years ago. Initially, only their insulinotropic effect on pancreatic β cells was known. Over the years, physiological and pharmacological effects of GIP and GLP1 in numerous extrapancreatic tissues were discovered which partially overlap, but may also be specific for GIP or GLP1 in certain target tissues.
View Article and Find Full Text PDFDeath and dysfunction of transplanted β-cells: lessons learned from type 2 diabetes?
Diabetes
January 2014
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
β-Cell replacement by islet transplantation is a potential curative therapy for type 1 diabetes. Despite advancements in islet procurement and immune suppression that have increased islet transplant survival, graft function progressively declines, and many recipients return to insulin dependence within a few years posttransplant. The progressive loss of β-cell function in islet transplants seems unlikely to be explained by allo- and autoimmune-mediated mechanisms alone and in a number of ways resembles β-cell failure in type 2 diabetes.
View Article and Find Full Text PDF